Print Page  Close Window
8-K
PARATEK PHARMACEUTICALS, INC. filed this Form 8-K on 01/04/2019
Entire Document
 

Slide 14

NUZYRA Opportunities Beyond Today’s Skin Treatment Options: Addressing Limited Formulations with Safety Concerns Vancomycin +/- Pip/Tazo Zyvox +/- Pip/Tazo Inpatient Rx OR NUZYRA as First-Line Therapy: Monotherapy, IV + Oral, when Vancomycin/Zyvox +/- Pip/Tazo are not options IDSA SSTI Guideline:1 SSTI: Skin and Soft Tissue Infection, pip/tazo: piperacillin/tazobactam 1. Stevens et al. Clin Infect Dis. 2014; 59(2):e10-52. 2. Barlam TF, et al. Clinical Infectious Diseases. 2016;62(10):e51–e77.